Drug intelligence / Profile preview

AP-60

Development stage: Preclinical
Lead developer: Aprogen
Modality: Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies

Overview

AP-60 is an investigational Antibody-cell Conjugate (ACC) developed by Aprogen, Inc. It functions as an inhibitor of Tumor-associated glycoprotein 72 (TAG-72), a protein often overexpressed in various cancers. Currently in preclinical development, AP-60 is being explored for its potential therapeutic application in neoplasms and digestive system disorders, with a specific focus on colorectal cancer.

Targets

TAG-72

Beyond the preview

Go deeper on AP-60.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP-60.

Explore the full profile